Gut-associated lymphoid tissue (GALT) dendritic cells (DCs) display a unique ability to generate CCR9^+α4β7^+ gut–tropic CD8^+ effector T cells. We demonstrate efficient induction of CCR9 and α4β7 on CD8^+ T cells in mesenteric lymph nodes (MLNs) after oral but not intraperitoneal (i.p.) antigen administration indicating differential targeting of DCs via the oral route. In vitro, lamina propria (LP)–derived DCs were more potent than MLN or Peyer’s patch DCs in their ability to generate CCR9^+α4β7^+ CD8^+ T cells. The integrin α chain CD103 (α2) was expressed on almost all LP DCs, a subset of MLN DCs, but on few splenic DCs. CD103^+ MLN DCs were reduced in number in CCR7^−/− mice and, although CD8^+ T cells proliferated in the MLNs of CCR7^−/− mice after i.p. but not oral antigen administration, they failed to express CCR9 and had reduced levels of α4β7. Strikingly, although CD103^+ and CD103^− MLN DCs were equally potent at inducing CD8^+ T cell proliferation and IFN-γ production, only CD103^+ DCs were capable of generating gut–tropic CD8^+ effector T cells in vitro. Collectively, these results demonstrate a unique function for LP-derived CD103^+ MLN DCs in the generation of gut-tropic effector T cells.

Antigen-dependent differentiation of naive T cells in lymphoid organs leads to the generation of effector T cells exhibiting a de novo capacity to enter peripheral extralymphoid tissues (1). Effector T cells generated in different lymphoid organs display distinct tissue tropism, a feature that appears to be regulated by an organ–specific induction of adhesion molecules and chemokine receptors during T cell priming (2–4). For example, T cells activated in mesenteric LNs (MLNs) draining the gut acquire high-level expression of the integrin α4β7 and the chemokine receptor CCR9, and these molecules are important for their subsequent localization to the small intestine (3, 5, 6). Conversely, T cells activated in skin-draining LNs acquire expression of E– and P-selectin ligands and CCR4 (2, 7) molecules that appear to direct T cells into inflamed skin (8–10).

DCs are critical for the generation of tissue-tropic effector T cell subsets. Thus, MLN or Peyer’s patch (PP) DCs are necessary and sufficient for the generation of CCR9^+α4β7^+ CD62L^− gut-homing T cells in vitro, whereas T cells activated by antigen-pulsed skin-draining peripheral LN (PLN) DCs are induced to express E– and P-selectin ligands (5, 7, 11, 12). Gut-associated lymphoid tissue (GALT), but not splenic, DCs were recently shown to convert dietary vitamin A to retinoic acid, which in turn induced T cell expression of CCR9 and α4β7 (13). Thus, the expression of retinoid dehydrogenase enzymes, catalyzing the sequential oxidation of vitamin A via retinal to retinoic acid appears in part to underlie their selective ability to generate gut-tropic T cells (13). Consistent with this possibility, T cells primed with fixed PP DCs failed to express CCR9 or α4β7 (14). The site and underlying signals where GALT DCs are imprinted with their ability to generate gut-tropic T cells remain unknown. Indeed, sorting of GALT DCs based on fixed PP DCs are necessary and sufficient for the generation of CCR9^+α4β7^+ gut-tropic T cells (5, 14).
Here, we show that the capacity to generate gut-tropic CD8+ effector T cells is present already among DCs in the small intestinal lamina propria (LP). Further, we identify a distinct subset of LP-derived DCs within the MLNs that express the epithelial–T cell associated integrin CD103 and have a unique capacity among MLN DCs to generate gut-homing T cells.

RESULTS
Oral administration of antigen leads to an efficient generation of CCR9+α4β7+ gut-tropic CD8+ T cells
CCR9 and α4β7 are poorly induced on CD8+ T cells proliferating in the MLNs after i.p. administration of antigen alone (5). To examine the generation of CCR9+α4β7+ T cells after oral antigen administration, TCR-transgenic OVA-specific OT-I cells were transferred into recipient mice, and the frequencies of OT-I cells expressing CCR9 and α4β7 in MLNs were examined 3 d after i.p. or oral administration of OVA (Fig. 1, A–C). Administration of OVA i.p. leads to a poor induction of CCR9 on responding T cells, and this was enhanced by coadministration of LPS (Fig. 1, B and C) as previously described (3, 5). In contrast, oral administration of OVA led to a strong induction of CCR9 on responding T cells both in the absence and presence of the mucosal adjuvant cholera toxin (CT; Fig. 1, B and C). A higher percentage of OT-I cells expressed CCR9 after antigen administration via the oral route as compared with the i.p. route, as well as when comparing carboxyfluorescein diacetate succinimidyl ester (CFSE)–labeled cells that had undergone the same number of cell divisions (not depicted), demonstrating that these differences do not reflect changes in OT-I cell cycle progression. Finally, expression of α4β7 on the transferred OT-I cells conformed to the same pattern as observed for CCR9, although the difference between oral and i.p. immunization was less pronounced.

CCR9 plays a central role in the recruitment of activated CD8+ T cells to the small intestinal epithelium after i.p. administration of OVA and adjuvant (3, 5). To determine whether CCR9 is important for this recruitment process of the immunization regime used, WT and CCR9−/− OT-I cells were cotransferred into WT recipient mice, and the ratio of the transferred cells in the MLN and intraepithelial lymphocyte (IEL) compartments was determined 3 d after oral or i.p. immunization in the absence or presence of adjuvant. Although CCR9 deficiency had no impact on the antigen-specific activation and expansion of OT-I cells in MLNs, the CCR9−/− OT-I cells were severely impaired in...
their ability to enter the small intestinal epithelium after both oral and i.p. immunization in the absence or presence of adjuvant (Fig. 1 D).

**LP DCs efficiently generate CCR9^+\alpha_4\beta_7^+ CD8^+ T cells in vitro**

The efficient induction of CCR9 and \alpha_4\beta_7 on CD8^+ T cells in the MLNs after oral compared with i.p. antigen administration suggested that these two immunization routes were inducing differential DC migration/activation or preferentially targeting different DC populations. There was no difference in the number or phenotype (CD40, CD80, CD86, and CD103 expression) of CD11c^-MHC class II^+ DCs in the MLNs 24 h after administration of OVA i.p. (5 mg) or orally (50 mg; unpublished data), indicating that differences resulting from oral versus i.p. antigen administration were caused by differential DC targeting. DCs are numerous throughout the intestinal LP and are thought to play an important role in the sampling and processing of oral antigen (15). Furthermore, LP DCs migrate from the intestinal LP to the MLNs under steady-state conditions, and this migration process is enhanced after oral administration of CT and after i.v. injection of LPS (16–18). We therefore determined whether LP DCs were capable of generating CCR9^+\alpha_4\beta_7^+ CD8^+ T cells in vitro. To obtain sufficient numbers of LP DCs for in vitro studies, DCs were expanded in vivo by s.c. injection of Flt3L–producing melanoma cells, as previously

**Figure 2.** LP dendritic cells are potent in generating CCR9^+\alpha_4\beta_7^+ CD8^+ T cells. OT-I cells were activated in vitro with SIINFEKL peptide–pulsed DCs purified from LP, MLNs, PP, or spleen. (A) OT-I cell proliferation in response to a graded number of indicated DCs as assessed by quantification of methyl-[3H]thymidine incorporation. Values represent mean ± SD. (B) CCR9 and (C) \alpha_4\beta_7 expression by CFSE-labeled OT-I cells was determined by flow cytometry after 4–5 d of co-culture with DCs. The percentage of positive cells among dividing OT-I cells is presented. DCs from Flt3L–treated mice were used in all experiments except experiment [expt] 4 in (B) and (C), where DCs were purified from pooled tissues of 10 untreated mice. *P < 0.05, SPL, spleen.

**Figure 3.** CD103 is expressed by the majority of LP DCs and a subset of MLN DCs. Leukocytes were isolated from the small intestinal LP, MLNs, and spleen and analyzed by flow cytometry using 7-AAD, anti-MHC class II–FITC, anti–CD11c–APC, and anti–CD103–PE mAbs. (A) Identification of CD11c^-MHC class II^+ (region I), CD11c^hi^-MHC class II^+ (region II), and CD11c^lo^-MHC class II^+ (region III) cells after gating on 7-AAD^- (live) cells. (B) Light scatter properties of the indicated populations of cells. (C–D) Representative histograms showing CD103 expression by LP cells (C) and MLN cells (D) using the region definitions depicted in (A). (E) Statistical analysis of CD103 expression by CD11c^-MHC class II^+ (region I) and CD11c^hi^-MHC class II^+ (region II) DCs from LP, MLNs, and spleen (mean ± SD; n = 9 for LP and MLNs, n = 6 for spleen). *P < 0.0005; **P < 0.0001 compared with LP equivalent. n.d., not done.
described (11). LP, MLN, PP, and splenic DCs, pulsed with OVA peptide, all induced efficient OT-I T cell proliferation (Fig. 2A). Phenotypic analysis of proliferating OT-I cells demonstrated that LP DCs were by far the most efficient at generating CCR9+ OT-I cells, followed by MLN and PP DCs (Fig. 2B). The greater capacity of LP DCs to induce CCR9 on T cells was not caused by differences in cell cycling, as similar differences were observed when comparing CFSE-labeled T cells that had undergone the same number of cell divisions (unpublished data). All intestinal DC subsets induced expression of αβ, by the OT-I cells and did not substantially differ in this capacity (Fig. 2C). OT-I cells activated by splenic DCs failed to express CCR9 and displayed relatively low levels of αβ, induction (Fig. 2, B and C), which was consistent with our previous results (5). Finally, data observed with Flt3L-treated mice were confirmed in one experiment using untreated mice, indicating that this procedure did not affect the outcome of our experiments (Fig. 2, B and C, experiment [expt] 4).

Small intestinal LP DCs express the integrin CD103

Given the more pronounced ability of LP DCs, as compared with MLN and PP DCs, to generate αβ+,CCR9+ gut-homing T cells, it seemed conceivable that the capacity of MLN DCs to confer gut tropism to T cells is associated with the presence of an LP-derived subset in the MLNs. We therefore performed extensive phenotypic analysis of LP, MLN, and splenic DCs in an attempt to identify a marker for LP-derived DCs in the MLNs. One of the molecules we examined was the integrin CD103 (αβ) because it is expressed by rat DCs in most epithelial tissues (19), has previously been reported to be expressed by murine LP DCs (20), and is up-regulated on effector CD8+ T cells soon after their entry into the small intestinal epithelium (21). CD103 was expressed by 80% of the CD11chighMHC class II+ DCs (region II) in LP and by 64% of the total CD11c+MHC class II+ LP DCs (region I; Fig. 3, A–E). In the MLNs, a substantially lower fraction of the CD11c+MHC class II+ DCs expressed CD103, and splenic DCs were largely CD103− (Fig. 3, D and E), which is in agreement with the results of Kilshaw (20). In the LP, an additional and distinct subset of CD11clowMHC class II+ cells that displayed the light scatter properties of granulocytes was identified (Fig. 3, A and B, region III). Only 5 ± 4% of these granular cells expressed CD103 (mean ± SD; n = 9; not depicted), and they were not present in the LP DC preparation used in the experiments shown in Fig. 2. Because these cells were not present in the MLNs (Fig. 3, A and B), we have not examined them further.

To confirm in situ the presence of CD103+ DCs within the small intestinal LP, immunofluorescent labeling of tissue sections was performed (Fig. 4). In initial studies using a primary anti-CD11c mAb combined with secondary detection reagents, an abundant number of CD11c+ cells were detected within the LP (not depicted). As many of these cells likely correspond to the numerous CD11clowMHC class II+ granular cells detected by flow cytometry (see Fig. 3A, region III), we used a less sensitive, directly fluorochrome-labeled mAb against CD11c to detect just the CD11chigh
Consistent with the FACS data, the vast majority of these CD11c<sup>high</sup>MHC class II<sup>+</sup> DCs within the LP expressed CD103 (Fig. 4).

Phenotypic analysis of CD103<sup>+</sup> DCs in the MLNs showed these cells to express high levels of MHC class II compared with their CD103<sup>−</sup> counterparts and higher, but still moderate, levels of CD40 and CD86 (Fig. 5). In the LP, all DCs expressed relatively low levels of CD40 and CD86 regardless of their expression of CD103, whereas CD103<sup>−</sup> LP DCs consistently expressed higher levels of CD80 than their CD103<sup>+</sup> counterparts or MLN DCs. CD62L expression, which is required for DC entry into the LNs directly from the blood stream (22), was confined to the CD103<sup>−</sup> DCs in MLNs and absent from all LP DCs (Fig. 5).

Collectively, there is a striking phenotypic resemblance between the CD103<sup>+</sup> MLN DCs and the previously described MHC class II<sup>high</sup> semimature skin-derived DCs present in skin-draining LNs (23–25). Chemokine receptor CCR7 is required for migration of these skin-resident DCs to draining LNs under both steady-state and inflammatory conditions (25, 26). We therefore examined the frequency of CD11c<sup>+</sup>MHC class II<sup>+</sup> DCs expressing CD103 in the MLNs of CCR7<sup>−/−</sup> and WT mice. The total number of CD11c<sup>+</sup>MHC class II<sup>+</sup> DCs was reduced by 70% in the MLNs of CCR7<sup>−/−</sup> mice compared with WT mice. Furthermore, only 18 ± 4% of the MLN DCs in CCR7<sup>−/−</sup> mice expressed CD103, compared with 36 ± 3% of MLN DCs in WT mice (mean ± SD; n = 5 in each group). Thus, although the MLNs of CCR7<sup>−/−</sup> mice had a reduced total number of DCs compared with WT mice, there was a more pronounced reduction in the CD103<sup>+</sup> DC population. In contrast, the total number of CD11c<sup>high</sup>MHC class II<sup>+</sup> LP DCs that expressed CD103 was similar in WT and CCR7<sup>−/−</sup> mice (unpublished data).

Generation of gut-homing T cells in MLNs requires a CCR7-dependent immigration of APCs

Next we used CCR7<sup>−/−</sup> mice for adoptive transfer experiments. We have observed that OVA-specific CD4<sup>+</sup> T cells fail to proliferate in the MLNs of CCR7<sup>−/−</sup> mice after oral administration of OVA (unpublished data), indicating that DC migration from the gut mucosa to the MLNs is perturbed in these mice. Similarly, OT-I cells failed to proliferate in the MLNs of CCR7<sup>−/−</sup> mice after oral administration of OVA and CT (unpublished data). Nevertheless, OT-I cells proliferated equally well in the MLNs of CCR7<sup>−/−</sup> and WT mice after i.p. administration of OVA and LPS (Fig. 6 A). Collectively, these results suggest that CCR7 is required for DC migration from the intestinal LP to the draining MLNs and that this process is necessary for CD8<sup>+</sup> T cell priming in the MLNs after oral immunization.

If LP-derived DCs are critical for the generation of gut-tropic T cells in the MLNs, one would thus expect T cells primed in the MLNs of CCR7<sup>−/−</sup> mice to fail to express CCR9. Consistent with this possibility, after i.p. immuniza-
Figure 6. CD8+ T cells primed in the MLNs of CCR7−/− mice fail to adopt a gut-tropic phenotype. CFSE-labeled OT-I cells were adoptively transferred into WT or CCR7−/− recipient mice. 3 d after i.p. immunization with OVA and LPS, MLNs were collected, and the phenotype of OT-I cells was determined by flow cytometry. (A) Representative data of CCR9, αβ, and CD62L expression by divided OT-I cells in the MLNs of WT versus CCR7−/− recipient mice. The CFSE gate is set to distinguish dividing from nondividing cells and is based on the CFSE intensity of OT-I cells in the PLNs of recipient mice (that do not divide) 3 d after oral OVA administration. The percentages indicate divided cells that express the markers shown. (B) Mean values ± SD obtained with three mice in each group.

CD103+ but not CD103− MLN DCs generate CCR9+αβ+high CD8+ T cells

Collectively, this line of experiments strongly suggested that CD103+ DCs derived from the intestinal LP are important for the generation of gut-tropic T cells in the MLNs. To directly address this possibility, CD103+ and CD103− DCs were sorted from the MLNs (Fig. 7 A) and pulsed with OVA peptide, and their ability to induce CCR9+ and αβ+ on responding OT-I cells was examined (Fig. 7). Both DC populations induced similar OT-I T cell proliferation, down-regulation of CD62L, and a similar percentage of IFN-γ-producing OT-I cells (Fig. 7, B, C, and F). In marked contrast, only CD103+ MLN DCs were capable of inducing CCR9 on responding OT-I cells (Fig. 7, D and F) and were also more efficient in their ability to induce αβ+ expression by the T cells, although this difference was less dramatic than observed for CCR9 (Fig. 7 D). Because αβ+ expression displays slow expression kinetics in vitro as compared with in vivo (11), we expanded the DC-primed OT-I cells by supplementing the cultures with IL-7 and IL-15 (27, 28). Although CCR9 levels were maintained after 3 d of expansion, a greater fraction of OT-I cells expressed αβ+. In addition, a large proportion of OT-I cells activated by CD103+ MLN DCs acquired expression of this integrin, although the proportion and levels remained lower than on OT-I cells activated by CD103− MLN DCs (Fig. 7, E and F). Finally, CD103+ MLN DCs also selectively induced CCR9 on responding CD4+ OT-II cells (Fig. 7 D); however, in contrast to OT-I cells, both DC subsets induced similar levels of αβ+ on responding OT-II cells after primary activation (Fig. 7 D) or after expansion with IL-7 and IL-15 (unpublished data). Collectively, these results demonstrate a unique ability of CD103+ MLN DCs in generating gut-tropic effector T cells.

DISCUSSION

We have identified a distinct subset of DCs expressing the integrin α chain CD103 that are responsible for generating CCR9+αβ+high gut-homing T cells in the MLNs. Most strikingly, CD103+ DCs, which include the majority of MLN DCs, can prime both CD4+ and CD8+ T cells in vitro but fail to induce CCR9 on these cells. We further demonstrated that, regardless of the immunization regime being used, CCR9-deficient CD8+ T cells are heavily disadvantaged in their capacity to enter the small intestinal epithelium, as compared with their CCR9-sufficient counterparts. Collectively, these results identify CD103+ DCs as potential novel targets for regulating T cell accumulation within the intestinal mucosa.

Several results from the current study suggest that murine CD103+ DCs in the MLNs derive from the intestinal LP. First, LP DCs, as CD103+ MLN DCs, were potent generators of gut-tropic T cells in vitro. Second, CD103 was expressed on almost all CD11chighMHC class II+ LP DCs. Third, the percentage of DCs that expressed CD103 was considerably reduced in the MLNs of CCR7−/− mice. Finally, there was a phenotypic resemblance between the CD103+ MLN DCs identified in the present study and the previously described skin-derived MHC class IIhigh semimature DCs in skin-draining LNs (23–25). Consistent with their LP origin, CD103 is expressed on almost all DCs in rat gut-draining LNs (19). We think it unlikely that CD103+ MLN DCs derive from PP, because in our hands PP DCs were not as potent as MLN DCs at generating gut-tropic T cells, and the percentage of DCs expressing CD103 in the PP did not exceed those in the MLNs (unpublished data). Indeed, recent data in pigs suggest that few if any DCs migrate from the PP to the MLNs (29), and the number of LP, but not PP, DCs is heavily reduced after i.v. injection of LPS into mice (18).

The origin of the CD103− MLN DCs remains elusive. We believe that the CD103− LP DCs derive from isolated lymphoid follicles (30) or represent recently recruited DCs that have yet to express CD103 and that these cells are not a major
source of CD103<sup>+</sup> MLN DCs. This belief is based on the finding that CD103<sup>-</sup> MLN DCs express far lower levels of MHC class II compared with CD103<sup>+</sup> LP DCs, display a very different phenotype than their CD103<sup>-</sup> MLN DC counterparts, and previous results that rat gut–draining lymph leukocytes depleted of CD103<sup>-</sup> cells are extremely poor in stimulating the primary mixed lymphocyte reaction (19), suggesting that few, if any, rat CD103<sup>+</sup> LP DCs migrate into the MLNs. The expression of CD62L by CD103<sup>+</sup> DCs in the MLNs indicates that at least some of these cells have entered directly from the blood via high endothelial venules, as previously reported to occur in popliteal LNs during viral infection (22).

The anatomical location and specific signals involved in imprinting MLN DCs with the ability to generate gut-tropic T cells are currently unknown. Clearly, these signals are not ubiquitously present within the MLNs, as CD103<sup>-</sup> MLN DCs were incapable of generating gut-tropic T cells. Furthermore, the ability of LP DCs to generate gut-tropic T cells strongly suggests that imprinting occurs before DC entry into the MLNs. In this regard, the association of CD103 with a DC’s ability to generate gut-tropic T cells may provide a clue. CD103 (α<sub>4β<sub>7</sub></sub>) is the α<sub>4β<sub>7</sub></sub> chain of the α<sub>4β<sub>7</sub></sub> integrin, expressed on the majority of human and mouse intestinal lymphocytes (31, 32), and mediates their adhesion to intestinal epithelial cells via interactions with E-cadherin (33). Importantly, effector CD8<sup>+</sup> T cells do not express CD103 before their entry into the intestinal mucosa but rapidly up-regulate this integrin after localizing to the intestinal epithelium (21).

CD8<sup>+</sup> T cells expressing a dominant-negative TGF-βII receptor express reduced levels of CD103 after their entry into
the intestinal epithelium (34), indicating an important role for TGF-β, potentially derived from intestinal epithelial cells (35), in CD103 induction. Should CD103 be a marker of DCs that have been exposed to epithelial cells and TGF-β, it would seem likely that epithelial-derived factors also play an important role in imprinting them with an ability to generate gut-tropic T cells. An additional, although as we believe, less likely possibility is that a subset of DC precursors that have already been imprinted with an ability to generate gut-tropic T cells selectively localize to the intestinal LP.

Although only CD103+ MLN DCs induced CCR9 on responding OT-I and OT-II cells, both CD103+ and CD103− MLN DCs were capable of inducing αβ7. These findings are consistent with several recent studies demonstrating a less stringent requirement for the induction of αβ7 compared with CCR9. Indeed, αβ7 is induced on T cells after prolonged activation in vitro by DCs from skin-draining LNs. Because αβ7 is detected on adoptively transferred CD4+ or CD8+ T cells in the MLNs but not PLNs after immunization of recipient mice (2, 5), αβ7 expression appears to be more stringently regulated during immune responses in vivo. Nevertheless, T cells primed in the MLNs of CCR7−/− mice, which contain few CD103+ DCs, failed to express CCR9 but showed a less dramatic reduction in αβ7 expression compared with T cells primed in the MLNs of WT mice. Because both αβ7 and CCR9 induction on T cells is dependent on intestinal DC production of retinoic acid (13), a potential explanation for these findings is that αβ7 requires lower levels of retinoic acid as compared with CCR9 for its induction and that the CD103− MLN DCs can produce low quantities of retinoic acid. Because of the limited number of cells obtained after purification and cell sorting of CD103+ and CD103− MLN DCs, we have not been able to examine the amount of retinoic acid generated by each of these populations. However, induction of αβ7 by lower levels of retinoic acid could potentially be explained through synergistic signals provided by co-stimulatory molecules. Indeed, up-regulation of αβ7 in vivo is partially blocked in the presence of a neutralizing antibody to CD40L (37), suggesting that OX40 signaling may act in synergy with retinoic acid to trigger expression of αβ7 by T cells. Consistent with a CD40-dependent expression of OX40L by DCs (38), we have also found that a neutralizing antibody to CD40L reduces the number of αβ7+ OT-I cells by ~50% after co-culture with MLN DCs, whereas CCR9 expression is unaffected by this treatment (unpublished data).

Several studies have demonstrated expression of CD103 on DCs both within and outside the small intestine (19, 20). In the rat, CD103 was originally identified through the mAb OX-62 raised against veiled cells obtained from the cannulated thoracic duct of mesenteric lymphadenectomized animals; however, it is also present on DCs in the thymus, cervical LNs, interstitium of the lung, portal triads of the liver, glomeruli of the liver, islet of Langerhans of the pancreas, and epithelium of choroid plexus, but not in heart and skeletal muscle (19). A similar distribution of CD103+ DCs has been reported in the mouse (20). We also confirm the findings of Kilshaw (20) that murine splenic DCs, in apparent contrast to DCs in the rat spleen (19), are largely CD103−. Thus, as with effector CD8+ T cells, CD103 expression on DCs appears to be primarily restricted to epithelial tissues or LNs draining such tissues. Finally, we have found that ~20% of DCs in skin-draining LNs express CD103 and that this frequency is also dramatically reduced in CCR7−/− mice (unpublished data). Collectively, these results indicate that CD103+ DCs may represent a unique population of DCs associated with epithelial tissues and that these cells are capable of migrating to local draining LNs. In this regard it will be of considerable interest to determine whether CD103+ DCs in LNs draining distinct epithelial tissues generate effector T cells with tropism for that particular site.

Finally, our results suggest that the efficient generation of gut-tropic T cells after oral compared with i.p. antigen administration is caused by a differential targeting of DCs. Furthermore, experiments in CCR7−/− mice revealed that oral-administered OVA does not reach the MLNs in soluble form in sufficient quantity to induce OT-I cell proliferation but must be transported to the MLNs by DCs. Thus, the enhanced generation of CCR9+αβ7high OT-I cells after oral immunization compared with i.p. immunization likely reflects enhanced antigen presentation by LP-derived DCs in the MLNs. Indeed, intestinal DCs display a pronounced migration into the draining MLNs under steady-state conditions (18, 39). How then is adjuvant functioning to enhance the generation of gut-tropic T cells? Because both oral CT and systemic LPS administration induce DC migration from the small intestinal LP into the draining MLNs (16–18), adjuvant likely promotes the generation of gut-tropic T cells by enhancing the number of intestinally imprinted LP-derived DCs in the MLNs. At this point, we cannot exclude the possibility that adjuvant also functions directly to mature the gut-imprinting ability of CD103+ DCs within the MLNs; however, it is notable that i.v. injection of LPS into rats almost completely emptied the small intestinal LP of DCs within 12 h, whereas the phenotype of the DCs in the gut-draining LNs and in the MLNs showed no apparent signs of maturation, as judged from expression levels of CD80 and CD86 (18).

In conclusion, we have demonstrated that the capacity to generate tissue-selective T cell subsets in the gut is highly restricted to a specialized subset of CD103+ MLN DCs most likely originating from the small intestinal LP. The presence of CD103+ DCs in LNs draining other epithelial tissues suggests that these cells may also provide important (but different) cues for T cell migration at these sites. Our results indicate that targeting the CD103+ intestinal DCs may provide a novel means of regulating intestinal immune responses. This may be of particular importance in the development of oral vaccines and in the treatment of chronic inflammatory bowel disease.
MATERIALS AND METHODS

Mice. OT-I, C57BL/6 (Ly5.1), and C57BL/6 mice were obtained from the Jackson Laboratory. OT-II mice were provided by M.-J. Wick (Gothenburg University, Gothenburg, Sweden). CCR9⁻/⁻ OT-I (provided by A. Würdel and B. Malissen, Institut national de la santé et de la recherche médicale, Parn, France) and Ly5.1⁺Ly5.2⁻ OT-I mice were generated as previously described (5). CCR7⁻/⁻ mice have been described previously (26). All mice were bred and maintained at the BioMedical Center animal facility of Lund University or at the central animal facility of Hannover Medical School, and all animal work was approved by the local ethical review boards in Lund and Hannover, respectively.

Reagents. In vitro cell culturing was performed in RPMI 1640 with 10% FCS, 2 mM L-Glutamine, 10 mM Hepes, 1 mM sodium pyruvate, 50 μM β-mercaptoethanol, 100 U/ml penicillin G, 100 μg/ml streptomycin sulfate, and 50 μg/ml gentamicin (all reagents were obtained from Gibco BRL), hereafter referred to as complete RPMI. Also, HBSS was obtained from Gibco BRL. OVA (grade VI; Sigma-Aldrich) was purified from endotoxins by Detoxi-Gel chromatography (Pierce Chemical Co.). Synthetic peptides were purchased from Innovagen. LPS (Escherichia coli, serotype (ES5101635)), CT (from Vibrio cholerae), DNAse I, collagenase type IV, and VIII, 7-amino-actinomycin D (7-AAD), PMA, ionomycin, and Brefeldin A were obtained from Sigma-Aldrich. Recombinant cytokines were purchased from R&D Systems, CFSE was purchased from Invitrogen, and methyl-[H]thymidine was obtained from GE Healthcare. The following antibodies were obtained from BD Biosciences: PE- and FITC-conjugated anti-CD103 (M290, IgG2a), unconjugated or PE-conjugated anti-αβ (DATK32, rat IgG2a), PE- or APC-conjugated anti-CD62L (MEL-14, rat IgG2a), biotinylated anti-CD80 (16-10A1, hamster IgG), PE-conjugated anti-IFN-γ (XM1G2.1, rat IgG1), PE-conjugated anti-Ly5.1 (A20, mouse IgG2a), FITC-conjugated anti-Ly5.2 (104, mouse IgG2a), and PE-conjugated anti-CD11c lineage hemocyanin (isotype control; A110-2, rat IgG2a). PE-labeled anti-CD54.2 (clone 104) was purchased from eBioscience. Anti-CCR7 (K629, polyclonal rabbit IgG) has been described previously (40). The following mAbs were produced from the hydribomas, purified, and labeled according to standard procedures: FITC anti-MHC class II (clone M5/114.15.2, rat IgG2b), Cy5 anti-CD11c (clone N418, hamster IgG), biotin anti-CD40 (clone FGK45, rat IgG2a), and biotin anti-CD86 (clone G41, rat IgG2a). PE-labeled anti-Ly5.1 (clone 104) was purchased from eBioscience. Anti-CR2 (K629, polyclonal rabbit IgG) has been described previously (40). The following mAbs were obtained from BD Biosciences: PE- and FITC-conjugated anti-CD103 (M290, IgG2a), unconjugated or PE-conjugated anti-αβ (DATK32, rat IgG2a), PE- or APC-conjugated anti-CD62L (MEL-14, rat IgG2a), biotinylated anti-CD80 (16-10A1, hamster IgG), PE-conjugated anti-IFN-γ (XM1G2.1, rat IgG1), PE-conjugated anti-Ly5.1 (A20, mouse IgG2a), FITC-conjugated anti-Ly5.2 (104, mouse IgG2a), and PE-conjugated anti-CD11c lineage hemocyanin (isotype control; A110-2, rat IgG2a).

DC purification. For in vivo expansion of DCs, C57BL/6 mice were injected s.c. on the dorsal flank with 15–20 × 10⁶ Flt3L-secreting B16 melanoma cells/mouse as previously described (11). Mice were killed 8–10 d later, and the indicated organs were removed and used for isolation of DCs. In experiments depicted in Fig. 2, DCs were purified from Flt3L-treated C57BL/6 mice. In all other experiments, untreated C57BL/6 mice were used. LN and spleen suspensions were prepared by pooling filtered through a 70-μm nylon mesh and subjected to EDTA treatment for a total of 3 h. To release LP leukocytes, the remaining tissue was incubated for 45 min at 37°C with 100 U/ml collagenase type VIII and 50 U/ml DNAse I diluted in HBSS containing 10% FCS and 10 mM Hepes. After digestion, the samples were shaken vigorously for 10 s, supernatants were collected by filtration through a nylon mesh, and tissue was subjected to a second round of enzymatic digestion. Leukocytes were further enriched on a 40:70 Percoll gradient where the interface was collected after centrifugation at 600 g for 20 min. DCs were finally immunomagnetically sorted as described in the previous section. For all DC preparations, >95% of positively selected cells expressed CD11c and >90% were CD11c⁺MHC class II⁺, as assessed by flow cytometry.

For sorting of MLN DCs into CD103⁺ and CD103⁻ subsets, CD11c⁺ cells were first enriched from total MLN cells by immunomagnetic cell sorting on a single LS column, followed by a second round of enzymatic digestion. Erythrocytes were removed from spleen and LP after removal of PP and epithelial cells. In brief, after extensive flushing with HBSS and removal of PP, the small intestine was cut longitudinally and then into 5-mm pieces. Epithelial cells were removed by incubating the tissue for 15 min at 37°C with 2 mM EDTA in HBSS supplemented with 10% FCS, followed by vigorous shaking for 10 s. The samples were filtered using a nylon mesh and subjected to further EDTA treatment for a total of three times. To release LP leukocytes, the remaining tissue was incubated for 45 min at 37°C with 100 U/ml collagenase type VIII and 50 U/ml DNAse I diluted in HBSS containing 10% FCS and 10 mM Hepes. After digestion, the samples were shaken vigorously for 10 s, supernatants were collected by filtration through a nylon mesh, and tissue was subjected to a second round of enzymatic digestion. Leukocytes were further enriched on a 40:70 Percoll gradient where the interface was collected after centrifugation at 600 g for 20 min. DCs were finally immunomagnetically sorted as described in the previous section. For all DC preparations, >95% of positively selected cells expressed CD11c and >90% were CD11c⁺MHC class II⁺, as assessed by flow cytometry.

In vivo cultures. Splenic CD8⁺ and CD4⁺ T cells were obtained from OT-I and OT-II mice, respectively, using biotinylated anti-CD8β mAb (53–5.8, rat IgG1; BD Biosciences), followed by streptavidin-conjugated magnetic beads or anti-CD4- conjugated beads, followed by purification on LS columns according to the manufacturer’s protocol (Miltenyi Biotec). Purified DCs from MLNs, PP, LP, or spleen were incubated for 1 h at 37°C with either 1 nM OVA323–339 SIINFEKL peptide (recognized by the OT-I TCR in the context of Kd) or 1 μM OVA323–339 ISQAVHAAHAAINEGR peptide (recognized by the OT-II TCR in the context of I-A²). After extensive washing, 10⁶ peptide-pulsed DCs were co-cultured with 2 × 10⁶ CFSE-labeled OT-I or OT-II cells in a final volume of 200 μl complete R10 medium using a flat-bottom 96-well plate. Primary cultures were analyzed by flow cytometry at day 4 of co-culture, and secondary cultures were analyzed after an additional 3 d of expansion in 1 ml of fresh, complete R10 medium supplemented with 10 ng/ml each of IL-7 and IL-15. Proliferation of 10⁶ OT-I cells/well in triplicate wells in response to a graded number of peptide-pulsed DCs was quantified during a 36-h period of co-culture by measuring methyl-[H]thymidine incorporation (1 μCi/ well) into DNA during the final 16 h of culture. For this purpose, cells were co-cultured in a flat-bottom 96-well plate, and incorporated radioactivity was counted in a liquid scintillation counter (Wallac 1450; Microbeta).

Adoptive transfer experiments. 3 × 10⁶ CD8β⁺ OT-I cells were injected i.v. into C57BL/6 or CCR7⁻/⁻ recipient mice. For adoptive transfers into the Ly5.1⁺ C57BL/6 recipients, we used Ly5.2⁺ OT-I cells or an equal number of Ly5.2⁺ CCR9⁻/⁻ OT-I and Ly5.1⁺ Ly5.2⁻ WT OT-I cells. The Ly5.2⁺ CCR7⁻/⁻ and C57BL/6/recipient mice received CFSE-labeled Ly5.1⁺ Ly5.2⁺ OT-I cells. 1 d after OT-I cell transfer, recipient mice were immunized either orally with 50 mg OVA with or without 20 μg CT or i.p. with 5 mg OVA with or without 50 μg LPS. 3 d later, mice were killed, and organs and tissues were collected. Isolation of small intestinal IEL and lymphocytes from LNs was performed as previously described (3). Donor OT-I cells were analyzed by flow cytometry and distinguished from the recipient cells based on Ly5.1/Ly5.2 expression.

Flow cytometry analysis. To determine the phenotype of DCs in LNs, spleen, and the small intestine LP, single-cell suspensions were prepared from the respective organ/tissue according to the protocols described in DC purification section. Adoptively transferred Ly5.2⁺ and Ly5.1⁺ Ly5.2⁻ OT-I cells

ARTICLE

Published October 10, 2005
were detected using FITC- or PE-labeled anti-Ly5.2 mAb and PE-conjugated anti-Ly5.1 mAb, respectively. PBS supplemented with 2% FCS and 2 mM EDTA was used for all incubations and washing procedures. All samples were preincubated with 2 μg/ml of anti-FcR mAb (2.4G2), and all incubations were performed on ice for 30 min with the viability marker 7-AAD included in the final incubation step. Analysis of intracellular IFN-γ was performed after a 4-h restimulation with 50 ng/ml PMA and 1 μg/ml ionomycin in the presence of 10 μg/ml Brefeldin A, followed by fixation and permeabilization with 4% paraformaldehyde and 0.5% saponin (Sigma-Aldrich). Data was acquired using a flow cytometer (FCSCalibur; Becton Dickinson), and data analysis was performed with the CellQuest (Becton Dickinson), FlowJo (Tree Star, Inc.), and FCSExpress (De Novo Software) software.

Tissue staining. Acetone-fixed cryostat sections of the small intestine jejunum were quenched with 0.3% H2O2, preincubated with 5% rat serum in Tissue staining. Acetone-fixed cryostat sections of the small intestine jejunum were quenched with 0.3% H2O2, preincubated with 5% rat serum in PBS, and then incubated with the viability marker 7-AAD in PBS supplemented with 2% FCS and 2 mM EDTA was used for all incubations and washing procedures. All samples were preincubated with 2 μg/ml of anti-FcR mAb (2.4G2), and all incubations were performed on ice for 30 min with the viability marker 7-AAD included in the final incubation step. Analysis of intracellular IFN-γ was performed after a 4-h restimulation with 50 ng/ml PMA and 1 μg/ml ionomycin in the presence of 10 μg/ml Brefeldin A, followed by fixation and permeabilization with 4% paraformaldehyde and 0.5% saponin (Sigma-Aldrich). Data was acquired using a flow cytometer (FCSCalibur; Becton Dickinson), and data analysis was performed with the CellQuest (Becton Dickinson), FlowJo (Tree Star, Inc.), and FCSExpress (De Novo Software) software.

Statistical analysis. All statistical analyses were performed using the two-tailed Mann-Whitney U test.

The authors have no conflicting financial interests.

This work was supported by grants from the Swedish Medical Research Council (VR-Medicine; 2003-5128); the Welcome Trust (075571/2/04/2); the Crafoordska Stiftelsen, Stockholm, Sweden; the Swedish Medical and Royal Physiographic Societies; the Swedish foundation for Strategic Research “Microbes and Man” and Individual Grant for the Advancement of Research Leaders II program; and the Deutsche Forschungsgemeinschaft (SFB621-TP1).

REFERENCES


